Furthermore, in RRMS, the percentages of naïve B cells and transitional B cells were higher in IFN-β-treated MS patients than in untreated MS patients (padj = 0.010 and 0.001, respectively). This evidence concerns the gene IFNB1 and myeloid sarcoma.